Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis C

Hepatology Research

Volumn 44, Issue 14, 2014, Pages E447-E454

  Nagaoki, Yuko ^a,x   Imamura, Michio ^a   Kawakami, Yoshiiku ^a   Kan, Hiromi ^a   Fujino, Hatsue ^a   Fukuhara, Takayuki ^a   Kobayashi, Tomoki ^a   Ono, Atsushi ^a   Nakahara, Takashi ^a   Naeshiro, Noriaki ^a   Urabe, Ayako ^a   Yokoyama, Satoe ^a   Miyaki, Daisuke ^a   Murakami, Eisuke ^a   Kawaoka, Tomokazu ^a   Tsuge, Masataka ^a   Hiramatsu, Akira ^a   Aikata, Hiroshi ^a   Takahashi, Shoichi ^a   Hayes, C Nelson ^a   Ochi, Hidenori ^b   Chayama, Kazuaki ^a,b   Aimitsu, Shiomi ^c   Aisaka, Yasuyuki ^d   Amano, Hajime ^e   Amimoto, Tatsuya ^f   Arataki, Keiko ^g   Asada, Nobuyuki ^h   Azakami, Takahiro ⁱ   Ishida, Kunio ^j   Ishihara, Hiroto ^k   Ishitobi, Tomokazu ^l   Ito, Hiroyuki ^m   Kamada, Koji ⁿ   Kamiyasu, Masaya ^o   Kawakami, Hiroiku ^p   Kira, Shinsuke ^q   Kitamoto, Mikiya ^r   Kodama, Hideaki ^g   Kohno, Hiroshi ^s   Kohno, Hirotaka ^s   Masanaga, Toshiyuki ^t   Miura, Toshio ^u   Mori, Nami ^d   Moriya, Takashi ^v   Nabeshima, Yutaka ^w   Nakamura, Toshio ^y   Nakanishi, Toshio ⁱ   Nakashio, Ryo ^z   Nonaka, Michihiro ^j   Ohbayashi, Makoto ^e   Takaki, Shintaro ^d   Takesaki, Eichi ^x   Tamura, Toru ^aa   Tsuji, Keiji ^ab   Waki, Koji ^ab   Watanabe, Masashi ^ac   Yamaguchi, Syuji ^ad   Yamashina, Keitaro ^c   more..

^a HIROSHIMA UNIVERSITY   (Japan)

^b INST OF PHYS AND CHEMICAL RESEARCH   (Japan)

^c HIROSHIMA GENERAL HOSPITAL   (Japan)

^d ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

^e Onomichi General Hospital   (Japan)

^f Amimoto Clinic   (Japan)

^g Hiroshima Kinen Hospital   (Japan)

^h Asada Hospital   (Japan)

ⁱ Miyoshi Cyuo Hospital   (Japan)

^j JA HIROSHIMA GENERAL HOSPITAL   (Japan)

^k National Hospital Organization   (Japan)

^l Chuden Hospital   (Japan)

^m Saiseikai Kure Hospital   (Japan)

ⁿ Shobara Red Cross Hospital   (Japan)

^o Kamiyasu Clinic   (Japan)

^p Kawakami Clinic   (Japan)

^q Saiseikai Hiroshima Hospital   (Japan)

^r HIROSHIMA PREFECTURAL HOSPITAL   (Japan)

^s Kure Medical Center   (Japan)

^t Masanaga Clinic   (Japan)

^u Akitsu Prefectural Hospital   (Japan)

^v Chugoku Rousai Hospital   (Japan)

^w Chuden Hospital   (Japan)

^x National Hospital Organization Higashihiroshima Medical Center   (Japan)

^y Tenjingawa Nakamura Clinic   (Japan)

^z Nakashio Clinic   (Japan)

^aa MAZDA HOSPITAL   (Japan)

^ab HIROSHIMA CITY ASA HOSPITAL   (Japan)

^ac Kuchiwa Clinic   (Japan)

^ad Kure Kyosai Hospital   (Japan)

more..

Author keywords

Chronic hepatitis C; Inteferon lambda 4; Rapid virological response; Sustained virological response; Telaprevir

Indexed keywords

EID: 84917744129     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12336     Document Type: Article

References (28)

1. Tsukuma H, Hiyama T, Tanaka S etal. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328: 1797-1801.
2. Takano S, Yokosuka O, Imazeki F etal. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 1995; 21: 650-655.
3. Shiratori Y, Shiina S, Imamura M etal. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan. Hepatology 1995; 22: 1027-1033.
4. McHutchison JG, Everson GT, Gordon SC etal.; PROVE1 Study Team. Telaprevir with peg-interferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-1838.
5. Jacobson IM, McHutchison JG, Dusheiko G etal. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
6. Hézode C, Forestier N, Dusheiko G etal.; PROVE2 Study Team. Telaprevir and peg-interferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-1850.
7. Kumada H, Toyota J, Okanoue T etal. Telaprevir with peg-interferon and ribavirin for treatment-naïve patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2012; 56: 78-84.
8. Hayashi N, Okanoue T, Tsubouchi H etal. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. J Viral Hepat 2012; 19: e134-142.
9. Ge D, Fellay J, Thompson AJ etal. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
10. Tanaka Y, Nishida N, Sugiyama M etal. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
11. Suppiah V, Moldovan M, Ahlenstiel G etal. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-1104.
12. Saito H, Ito K, Sugiyama M etal. Factors responsible for the discrepancy between IL28B polymorphism prediction and the viral response to peginterferon plus ribavirin therapy in Japanese chronic hepatitis C patients. Hepatol Res 2012; 42: 958-965.
13. Akuta N, Suzuki F, Hirakawa M etal. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peg-interferon and ribavirin. Hepatology 2010; 52: 421-429.
14. Chayama K, Hayes CN, Abe H etal. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. J Infect Dis 2011; 204: 84-93.
15. Prokunina-Olsson L, Muchmore B, Tang W etal. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013; 45: 164-171.
16. Nozawa Y, Umemura T, Katsuyama Y etal. Genetic polymorphism in IFNL4 and response to pegylated interferon-α and ribavirin in Japanese chronic hepatitis C patients. Tissue Antigens 2014; 83: 45-48.
17. Akuta N, Suzuki F, Sezaki H etal. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol 2006; 78: 83-90.
18. Fellay J, Thompson A, Ge D etal. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010; 464: 405-408.
19. Ochi H, Maekawa T, Abe H etal. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy-a genome-wide study of Japanese HCV virus patients. Gastroenterology 2010; 139: 1190-1197.
20. Suzuki F, Suzuki Y, Akuta N etal. Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. Hepatology 2011; 53: 415-421.
21. Motomura T, Koga E, Taketomi A etal. Efficacy of splenectomy in preventing anemia in patients with recurrent hepatitis C following liver transplantation is not dependent on inosine triphosphate pyrophosphatase genotype. Hepatol Res 2012; 42: 288-295.
22. Ohnishi Y, Tanaka T, Ozaki K, Yamada R, Suzuki H, Nakamura Y. A high-throughput SNP typing system for genome-wide association studies. J Hum Genet 2001; 46: 471-477.
23. Tsukada H, Ochi H, Maekawa T etal. A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C. Gastroenterology 2009; 136: 1796-1805.
24. Bibert S, Roger T, Calandra T etal. IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J Exp Med 2013; 210: 1109-1116.
25. Reesink HW, Zeuzem S, Weegink CJ etal. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006; 131: 997-1002.
26. Poordad F, McCone J Jr, Bacon BR etal. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
27. Suzuki F, Suzuki Y, Sezaki H etal. Exploratory study on TVR given every 8h at 500mg or 750mg with peg-interferon-alpha-2b and ribavirin in hepatitis C patients. Hepatol Res 2013; 43: 691-701.
28. Kawakami Y, Suzuki F, Karino Y etal. Telaprevir is effective given every 12 hours at 750 mg with peginterferon-alfa-2b and ribavirin to Japanese patients with HCV-1b IL28B rs8099917 TT. Antivir Ther 2013; [Epub ahead of print].